Tag Archive for: Jefferies

Optimum’s hot topic: Investors look ahead to ’25 at London Life Sciences Week

By Richard Staines London Life Sciences Week has become a major fixture on the biotech calendar with two conferences – the LSX Inve$tival and the Jefferies London Healthcare Conference – plus the LSX Lifestars Awards all falling within one working week.  This year’s Jefferies event expanded from its traditional home at the Waldorf Astoria Hotel […]

Weekly round-up: How do you turn a 10-person biotech into a $1.1 billion company sale in the space of seven years?

During the BIO-Europe conference in Stockholm, Optimum co-hosted a special reception featuring a fireside chat with Renée Aguiar-Lucander, former CEO of Calliditas, who led the Swedish company since 2017 until recently – taking it from small biotech to its $1.1 billion acquisition. Here, we tell the story of her remarkable seven-year journey with the firm.  Novo […]

Mapping out the top life science conferences to attend in the next 6 months

Will we see you there? The Optimum team has taken a moment to map out the top life science conferences to attend in the next six months. Believe it or not, now is the time to be organising your 2025 conference calendar to maximise the opportunities these major life sciences events present. Secure your travel […]

The ‘must-attend’ Healthcare conferences Autumn / Winter 2024

With the summer holidays drawing to a close, now is the time to be organising your conference calendar to maximise the opportunities these major events in life sciences present. Secure your travel and accommodation while prices are attractive, and availability is high.  As an official partner to many of the top events, Optimum is pleased […]

Resolution Therapeutics to Participate in the Jefferies Global Healthcare Conference

Edinburgh and London, UK, 28 May 2024 – Resolution Therapeutics Limited (“Resolution” or “Company”), a clinical-stage biopharmaceutical company pioneering engineered autologous macrophage cell therapies to transform the treatment of inflammatory organ diseases, today announced that Amir Hefni, Ph.D., Chief Executive Officer, and Simon Ramsden, Chief Financial Officer, will participate in meetings with investors at the […]